Physician profile
Stanley Wiggins
NPI 1437131604
$1,647.76
in general payments reported to CMS, 2019-2025
18 companies · $166 in 2025
The $166 reported for 2025 was more than what a typical Pediatrics provider received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $226 · 2020: $28.54 · 2021: $88.69 · 2022: $208 · 2023: $283 · 2024: $646 · 2025: $166.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,096.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,095.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $435.75 | 2021-2025 | Qelbree, Qelbree |
| Ironshore Pharmaceuticals INC. | $246.53 | 2019-2024 | Jornay Pm |
| Merck Sharp & Dohme LLC | $222.61 | 2019-2025 | Gardasil 9, Vaxneuvance, M-M-R II |
| Corium, LLC | $195.60 | 2022-2024 | Azstarys |
| Pfizer INC. | $168.07 | 2019-2025 | |
| Sanofi Pasteur INC. | $56.85 | 2019-2025 | |
| Collegium Pharmaceutical, INC. | $50.47 | 2025 | Jornay Pm |
| Shire North American Group INC | $42.53 | 2019 | |
| Novo Nordisk INC | $39.66 | 2023-2025 | Ozempic, Rybelsus, Tresiba |
| Dexcom, INC. | $39.06 | 2023-2024 | Dexcom G6 Transmitter |
| Tris Pharma INC | $29.55 | 2019-2021 | |
| Kaleo, INC. | $28.87 | 2019 | |
| Biomarin Pharmaceutical INC. | $21.51 | 2024 | Voxzogo 1.2mg |
| Lilly USA, LLC | $17.39 | 2024 | Jardiance |
| Astrazeneca Pharmaceuticals Lp | $14.65 | 2023 | Breztri |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neos Therapeutics, Lp | $13.95 | 2022 | |
| Noven Therapeutics, LLC | $13.88 | 2025 | Xelstrym |
| Glaxosmithkline, LLC. | $10.83 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stanley Wiggins listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.